Truist Financial analyst David S Macdonald maintains $Encompass Health (EHC.US)$ with a buy rating, and sets the target price at $116.
According to TipRanks data, the analyst has a success rate of 62.7% and a total average return of 13.6% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Encompass Health (EHC.US)$'s main analysts recently are as follows:
Encompass Health's recent earnings results were described as 'refreshing' and serve to underscore its 'exceptionally strong fundamentals,' which are considered to be largely shielded from the impending election-related risks.
The firm suggests that Encompass Health's third-quarter outcomes appear robust, marked by a 4% EBITDA outperformance due to better same-store volumes. The firm remains positive on Encompass Health's equity, citing solid fundamentals and resistance to election-related fluctuations.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
